Patrícia Pacheco Viola, Matheus Wohlfahrt Baumgarten, Dimitris Rucks Varvaki Rados, Letycia Ribeiro, Ana Luiza Maia, Iuri Martin Goemann
{"title":"Reciprocal cancer risks between thyroid and breast cancer: a systematic review and meta-analysis.","authors":"Patrícia Pacheco Viola, Matheus Wohlfahrt Baumgarten, Dimitris Rucks Varvaki Rados, Letycia Ribeiro, Ana Luiza Maia, Iuri Martin Goemann","doi":"10.1530/ERC-24-0338","DOIUrl":null,"url":null,"abstract":"<p><p>Thyroid cancer (TC) and breast cancer (BC) are common in females, with growing evidence of their higher-than-expected co-occurrence. The purpose of this systematic review and meta-analysis was to evaluate the relationship between TC and BC and to examine the likelihood of developing BC after TC (TC1-BC2) and TC after BC (BC1-TC2). A systematic search was conducted in PubMed and Embase for articles with epidemiological evidence of TC and BC, published until 2024. For BC1-TC2 studies, subgroup analysis was performed on age at diagnosis and treatment type. The standardized incidence ratio (SIR) was used to calculate the risk of second primary malignancy. The MOOSE guidelines were followed, and the Newcastle-Ottawa scale was used to assess the quality of studies. Sixteen studies comprising 511,787 patients were included in the meta-analysis of TC1-BC2 and showed an increased risk of BC after TC (SIR = 1.4, 95% CI: 1.2-1.6, P < 0.01). Moreover, 28 studies with 2,486,870 patients were included for the BC1-TC2 meta-analysis and also demonstrated an increased risk of TC after BC (SIR = 1.5, 95% CI: 1.3-1.7, P < 0.01). The risk of TC was higher in BC patients under 50 (SIR = 1.8, 95% CI: 1.2-2.3) and in those treated with chemotherapy (SIR = 1.6, 95% CI: 1.5-1.7). Radiotherapy for BC was not linked to an increased risk of TC. Here, we demonstrated an increased risk of TC or BC as secondary malignancies. Furthermore, studies are needed to better understand this association and its implications for patient follow-up and management strategies.</p>","PeriodicalId":93989,"journal":{"name":"Endocrine-related cancer","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine-related cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1530/ERC-24-0338","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/1 0:00:00","PubModel":"Print","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Thyroid cancer (TC) and breast cancer (BC) are common in females, with growing evidence of their higher-than-expected co-occurrence. The purpose of this systematic review and meta-analysis was to evaluate the relationship between TC and BC and to examine the likelihood of developing BC after TC (TC1-BC2) and TC after BC (BC1-TC2). A systematic search was conducted in PubMed and Embase for articles with epidemiological evidence of TC and BC, published until 2024. For BC1-TC2 studies, subgroup analysis was performed on age at diagnosis and treatment type. The standardized incidence ratio (SIR) was used to calculate the risk of second primary malignancy. The MOOSE guidelines were followed, and the Newcastle-Ottawa scale was used to assess the quality of studies. Sixteen studies comprising 511,787 patients were included in the meta-analysis of TC1-BC2 and showed an increased risk of BC after TC (SIR = 1.4, 95% CI: 1.2-1.6, P < 0.01). Moreover, 28 studies with 2,486,870 patients were included for the BC1-TC2 meta-analysis and also demonstrated an increased risk of TC after BC (SIR = 1.5, 95% CI: 1.3-1.7, P < 0.01). The risk of TC was higher in BC patients under 50 (SIR = 1.8, 95% CI: 1.2-2.3) and in those treated with chemotherapy (SIR = 1.6, 95% CI: 1.5-1.7). Radiotherapy for BC was not linked to an increased risk of TC. Here, we demonstrated an increased risk of TC or BC as secondary malignancies. Furthermore, studies are needed to better understand this association and its implications for patient follow-up and management strategies.
甲状腺癌(TC)和乳腺癌(BC)在女性中很常见,越来越多的证据表明它们的共存率高于预期。本系统综述和荟萃分析的目的是评估TC与BC之间的关系,并检查TC (TC1-BC2)和BC (BC1-TC2)后发生BC的可能性。系统检索PubMed和Embase中截至2024年发表的具有TC和BC流行病学证据的文章。对于BC1-TC2研究,对诊断年龄和治疗类型进行亚组分析。标准化发病率(SIR)用于计算第二原发恶性肿瘤(SPM)的风险。遵循MOOSE指南,使用纽卡斯尔-渥太华量表评估研究质量。16项研究包括511,787例患者纳入TC1-BC2的荟萃分析,结果显示TC后BC的风险增加(SIR = 1.4, 95% CI 1.2-1.6, p